Alvotech is a global biopharmaceutical company singularly focused on the development and manufacture of biosimilar medicines for patients worldwide. Founded on the principle of improving access to high-quality, affordable biologics, Alvotech leverages its fully integrated platform, from cell line development to commercial manufacturing, to bring critical treatments to market. The company's pipeline spans various therapeutic areas, aiming to address unmet medical needs and enhance healthcare sustainability through its innovative biosimilar solutions.
Serves as Alvotech's global corporate headquarters and houses a state-of-the-art, vertically integrated research, development, and cGMP manufacturing facility for biosimilars.
Advanced, fully integrated biopharmaceutical facility with capabilities for cell line development, process development, analytical testing, and large-scale commercial manufacturing. Designed for flexibility and efficiency in biosimilar production.
A dynamic and science-driven environment fostering innovation, collaboration, and a commitment to quality. Employees are dedicated to the mission of improving global access to affordable medicines.
The Reykjavik facility is the cornerstone of Alvotech's end-to-end biosimilar development and manufacturing strategy, enabling control over the entire value chain and ensuring high-quality production standards for global markets.
Alvotech operates a global network supporting end-to-end biosimilar development and commercialization. This includes R&D and manufacturing in Iceland, commercial operations in Switzerland, manufacturing in Germany, and a strategic presence in the USA. The company collaborates with a network of global and regional partners for clinical trials, regulatory submissions, and commercial distribution of its biosimilars in markets across North America, Europe, Asia-Pacific, Latin America, and the Middle East.
Sæmundargata 15-19
Reykjavik
Capital Region
Iceland
Address: Alvotech Swiss AG, Tessinerplatz 7, 8002 Zürich, Switzerland
To drive Alvotech's commercial strategy and market access for its biosimilar portfolio across Europe and other international markets (excluding the US).
Address: Alvotech Germany GmbH, Karl-Heinz-Beckurts-Straße 13, 52428 Jülich, Germany
To provide specialized manufacturing capabilities and capacity for Alvotech's growing pipeline of biosimilar products, supporting both clinical and commercial supply needs.
Address: Alvotech USA Inc., (Specific address may vary, RTP area)
To establish and expand Alvotech's presence in the U.S., facilitating market entry and commercialization of its biosimilar products.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Alvotech' leadership includes:
Alvotech has been backed by several prominent investors over the years, including:
Alvotech has experienced several key executive transitions in the past year (June 2023 - June 2024), notably the appointment of founder Robert Wessman as CEO, a new CFO, a new General Counsel, and a new CCO for the US market, signaling strategic shifts and a focus on commercial growth.
Discover the tools Alvotech uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Alvotech commonly utilizes email formats such as [first_name].[last_name]@alvotech.com or [first_initial][last_name]@alvotech.com. For executives and general inquiries, specific departmental or role-based emails might also be in use.
firstname.lastname@alvotech.com
Format
jane.doe@alvotech.com
Example
90%
Success rate
Alvotech Press Release • June 3, 2024
Alvotech and Teva Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI® (adalimumab-ryvk) injection, a high-concentration, citrate-free biosimilar to Humira®. This marks a significant milestone for Alvotech in providing a key biosimilar to the U.S. market....more
Alvotech Press Release • May 23, 2024
Alvotech reported its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate achievements, including progress in its biosimilar pipeline and commercial partnerships....more
Alvotech Press Release • May 7, 2024
Alvotech announced that its Board of Directors has appointed Robert Wessman, Alvotech’s Founder and Chairman, as Chief Executive Officer, effective May 7, 2024. Mr. Wessman succeeded Mark Levick, who stepped down as CEO....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Alvotech, are just a search away.